跳至主要内容
临床试验/NCT02265263
NCT02265263终止不适用

Biomarker Development for Postoperative Cognitive Impairment in the Elderly (BioCog)

Charite University, Berlin, Germany2 个研究点 分布在 2 个国家目标入组 1,054 人开始时间: 2014年10月最近更新:
适应症

试验速览

阶段
不适用
状态
终止
入组人数
1,054
试验地点
2
主要终点
Incidence of Delirium

研究概览

简要总结

The research leading consortium to these results has received funding from the European Union Seventh Framework Programme [FP7/2007-2013] under grant agreement no 602461 (www.biocog.eu).

The investigators will establish valid biomarkers panels (neuroimaging and molecular) for risk and clinical outcome prediction of postoperative delirium (POD)/postoperative cognitive deficit (POCD) in elective surgical patients (Age ≥ 65 years) in study centers in Berlin,Germany (data collection within 2 years after initial hospital stay) and Utrecht, The Netherlands (data collection within 1 year after initial hospital stay), thereof cerebrospinal fluid (only once on day of surgery in patients with planned spinal anesthesia/combined spinal epidural analgesia in patients, only in Berlin).

A control group of ASA II/III- patients is collected for measuring the learning experience during the cognitive testings. The participants are matched on age, education, and gender to the study patients. The ASA II/III- control patients receive additionally MRI-scan (3 Tesla) at baseline, after 3 months and after 1 (Utrecht) and 2 years (Berlin).

To analyze scanner variability we additionally measure at maximum 20 subjects (Age ≥ 65 years, ASA I and II) from Utrecht in the MRI scanner (3-Tesla) in Berlin and vice versa.

A study group at maximum (n= 80) and is collected for measuring 7 Tesla MRI at two timepoints (Baseline and 90 days).The primary endponit of this substudy is gamma amino-butyric acid concentration in CNS after 3-months (measured by MRI). A retrospective comparison group (extracting 8000 intensive care unit patient data from the patient data management system during the BioCog study period in 2016) to analyse economic effects that are caused by the implementation of quality indicators in health care.

An interim-analysis is performed on the primary endpoint after 400 included patients.

The resulting (multivariate) expert system is expected: 1) to support clinical decision-making in patient care, e.g. to balance the individual POD/POCD risk against the expected overall clinical outcome of an (elective) surgical intervention, 2) to allow the design of more sophisticated and hypothesis-driven clinical studies and drug trials (translational research) in the future. The latter will be possible on the basis of biomarker-based sub-grouping of patients and a better understanding of relevant pathophysiological processes.

Furthermore, a state-of-the art clinical database and biobank will be created that does not yet exist worldwide. Both the expert system and the reference database/biobank will expand the leadership of the contributing academic institutions in this particular research area. In addition, the newly created biobank will become an integral part of the European Biobanking and Biomolecular Resources Research Infrastructure (BBMRI) which allows top address specific and hypothesis-driven research questions.

Most notably, the developed (multivariate) expert system also has the potential for commercialization. Possible customers are: 1) physicians and hospital departments being involved in pre-surgical decision making, 2) pharmaceutical industry intending to conduct biomarker-based drug trials in POD/POCD.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
65 Years 至 —(Older Adult)
性别
All
接受健康志愿者

入选标准

  • Male and female patients aged ≥ 65 years, of European descent (Caucasian)
  • Elective surgery with an expected operative time ≥ 60 minutes
  • Ability to give informed consent after receiving spoken and written information of the study
  • Eligibility for magnetic resonance Imaging

排除标准

  • Mini-Mental-State-Examination ≤ 23 points
  • Homelessness or other circumstances where the patient would not be reachable by phone or postal services during follow-up.
  • Participation in another prospective interventional clinical study during participation in this clinical study during hospital stay
  • Accommodation in an institution due to an official or judicial order
  • Missing informed consent for saving and hand out pseudonymous data
  • Neuropsychiatric morbidity, which limits the conduction of the neurocognitive testing
  • Anacusis or Hypoacusis, which limits the conduction of the neurocognitive testing
  • Intraoperative clectroencephalography - examinations (Study Group Berlin):
  • Exclusion criteria:
  • Neurological preconditions
  • Proposed neurological surgery
  • Control Group (Berlin/Utrecht):
  • Inclusion criteria:
  • Male and female patients aged ≥ 65 years, of European descent (Caucasian)
  • ASA II and III patients
  • No operation in the last half year before study inclusion
  • Eligibility for magnetic resonance Imaging
  • Exclusion Criteria:
  • Mini-Mental-State-Examination ≤ 23 Points
  • Missing informed consent for saving and hand out pseudonymous data
  • Neuropsychiatric morbidity, which limits the conduction of the neurocognitive testing
  • Anacusis or Hypoacusis, which limits the conduction of the neurocognitive testing
  • Taking psychothropic drugs (including sleep-inducing drug and benzodiazepine) on a regular basis and substances, which limit the conduction of the neurocognitive testing
  • Control Group (Utrecht) - Scannervariability:
  • Inclusion criteria:
  • Male and female patients aged ≥ 65 years, of European descent (Caucasian)
  • ASA I and II patients
  • No operation in the last half year before study inclusion
  • Eligibility for magnetic resonance Imaging
  • Study Group (Berlin) - 7 Tesla MRI:
  • Criteria as of the 3-Tesla- study group and additionally:
  • Exclusion criteria:
  • absolute 7 - Tesla MRI-contraindications
  • relative 7 - Tesla MRI-contraindications

结局指标

主要结局

Incidence of Delirium

时间窗: Participants will be followed for the duration of hospital stay, an expected average of 7 days

Postoperative delirium rate, defined according to Diagnostic and Statistical Manual of Mental Disorders (DSM-V) and/or as ≥ 2 cumulative points in the nursing Delirium Screening Scale (Nu-DESC) and/or a positive Confusion Assessment Method (CAM) and/or Confusion Assessment Method for the Intensive Care Unit (CAM-ICU) score and/or patient chart review that shows descriptions of delirium.

Incidence of postoperative cognitive deficit (POCD)

时间窗: Up to 3 months after the operation

POCD will be measured by a defined Cambridge Neuropsychological Test Automated Battery (CANTAB) POCD will be measured by a defined Cambridge Neuropsychological Test Automated Battery (CANTAB) and paper pencil tests (TMT A und B, Grooved Pegboard) and the Mini - Mental State Examination (MMSE)

次要结局

  • Incidence of subsyndromal postoperative delirium(Participants will be followed for the duration of hospital stay, an exspected average of 7 days)
  • Hand grip strength test(3 months, 1, 2 and 5 years after the operation)
  • Malnutrition(3 months, 1, 2 and 5 years after the operation)
  • Duration of Delirium(Participants will be followed for the duration of hospital stay, an exspected average of 7 days)
  • Duration of subsyndromal postoperative delirium(Participants will be followed for the duration of hospital stay, an exspected average of 7 days)
  • Intensive care unit length of stay(Participants will be followed for the duration of intensive care unit stay, an expected average of 5 days)
  • Socioeconomic characteristics(3 months, 1 year after the operation)
  • Hospital length of stay(Participants will be followed for the duration of hospital stay, an exspected average of 7 days)
  • Postoperative organ complications(Participants will be followed for the duration of hospital stay, an exspected average of 7 days)
  • Incidence of postoperative cognitive deficit(1 year, 2 years, 5 years after the operation)
  • Barthel Index(3 months, 1, 2 and 5 years after the operation)
  • Health related quality of life(3 months, 1, 2 and 5 years after the operation)
  • Mobility(3 months, 1, 2 and 5 years after the operation)
  • Neuroimaging Biomarker(3 months, 1, 2 and 5 years after the operation)
  • Instrumental activities of daily living scale(3 months, 1, 2 and 5 years after the operation)
  • Molecular Biomarker(3 months)
  • Health related Quality of life(3 months, 1 year after the operation)
  • Light Levels (lux)(Study center Berlin: Participants will be followed for the duration of hospital stay, an exspected average of 7 days)
  • Depression(Participants will be followed for the duration of hospital stay, an exspected average of 7 days)
  • Heart rate variability(Study center Berlin: Participants will be followed for the duration of hospital stay, an exspected average of 7 days)
  • Light frequencies(Study center Berlin: Participants will be followed for the duration of hospital stay, an exspected average of 7 days)
  • Anxiety(Participants will be followed for the duration of hospital stay, an exspected average of 7 days)
  • Mortality(3 months, 1, 2 and 5 years after the operation)
  • Depth of consciousness index(At time of surgery)
  • Electroencephalography (EEG)- Mapping(At time of surgery)
  • Intraoperative cerebral oxymetry(At time of surgery)
  • Changes of Electroencephalography(Participants will be followed up until the end of postanesthesia care unit, an exspected average of 2 days)
  • Depth of sedation(At time of surgery and Participants will be followed for the duration of intensive care unit stay, an expected average of 5 days)
  • Pain Scales(3 months)
  • Quality indicators of intensive care unit(Participants will be followed for the duration of intensive care unit stay, an expected average of 5 days)
  • Glucosevariability(At time of surgery and Participants will be followed for the duration of intensive care unit stay, an expected average of 5 days)
  • Frailty(3 months, 1, 2 and 5 years after the operation)
  • Coagulationdisorder of the blood(3 months)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Claudia Spies

Univ.-Prof. Dr. med. C. Spies

Charite University, Berlin, Germany

研究点 (2)

Loading locations...

相似试验

Biomarker Development for Postoperative Cognitive... | 临床试验